MedTrace Logo

Assessment of Change in Atherosclerotic Plaque by Serial CCTA

NCT03414840 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2018-06-29

No results posted yet for this study

Summary

Assessment of Change in AtheROSclerotic Plaque by Serial CCTA (ACROSS) is designed as a prospective observational study which aim is to demonstrate the effect of statins on coronary atherosclerosis, assessed by quantitative analysis of CCTA.

Conditions

Interventions

DRUG

Atorvastatin

Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical Corp.

    collaborator INDUSTRY

  • Yonsei University

    lead OTHER

Principal Investigators

  • Hyuk-Jae Chang, MD, PhD · Yonsei University

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2020-02-28
Completion
2020-10-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03414840 on ClinicalTrials.gov